



## Letter to the Editor

**Primary biliary cholangitis with autoimmune hepatitis features: What's the appropriate criteria to evaluate the treatment-response?**


Dear Editor,

We read with interest the recent article by Fernando et al. [1] mainly evaluated treatment response in a cohort of primary biliary cholangitis (PBC) patients. We should applaud their work for they raised the concept that the response rate of PBC patients with AIH features could be better, however, results from the current study could be interpreted with the following considerations.

As the authors revealed, five patients may meet Paris criteria for the diagnosis of PBC-AIH overlap syndrome [2]. Patients who met suggested response criteria for both PBC and AIH may be considered biochemical responders as used in another study [3]. For PBC part, ALP is actually a recognized surrogate marker for PBC response, however, it may not be a convincing evidence that the response is anyway different. Another comprehensive comparison including both PBC and AIH parts between PBC-only patients and those with AIH features to evaluate the treatment response would be useful.

Furthermore, as the majority of patients were in Ludwig's stage I and no patient developed cirrhosis during the follow-up, why the authors used Barcelona criteria only for treatment response? Barcelona criteria alone may be too simple for the outcome assessment of PBC. The authors are welcomed to make an analysis by Paris 2 criteria to offer a more robust conclusion.

**Declaration of funding interests**

Nothing to report.

**Conflict of interest**

The authors have no conflict of interest to declare.

**References**

- [1] Mane F, Cardoso H, Liberal R, Lopes S, Pereira P, Goncalves R, et al. Treatment response in primary biliary cholangitis: the role of autoimmune hepatitis features. *Ann Hepatol* 2019.
- [2] Chazouilleres O, Wendum D, Serfaty L, Montebault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *Hepatology* (Baltimore, MD) 1998;28: 296–301.
- [3] Ozaslan E, Efe C, Heurgue-Berlot A, Kav T, Masi C, Purnak T, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. *Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc* 2014;12:863–9.

Xiaoli Fan  
Haoran Wang  
Mengyi Shen  
Li Yang\*

*Department of Gastroenterology and Hepatology,  
West China Hospital, Sichuan University, 37 Guoxue  
Lane Chengdu, 610041 Sichuan, People's Republic of  
China*

\* Corresponding author.

E-mail address: [yangli\\_hx@scu.edu.cn](mailto:yangli_hx@scu.edu.cn) (L. Yang)

Available online 30 June 2019